Jacqulyne Robichaux
Overview
Explore the profile of Jacqulyne Robichaux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le X, Negrao M, Reuben A, Federico L, Diao L, McGrail D, et al.
J Thorac Oncol
. 2021 Jan;
16(4):583-600.
PMID: 33388477
Introduction: Lung adenocarcinomas harboring EGFR mutations do not respond to immune checkpoint blockade therapy and their EGFR wildtype counterpart. The mechanisms underlying this lack of clinical response have been investigated...
2.
Nilsson M, Robichaux J, Herynk M, Cascone T, Le X, Elamin Y, et al.
J Thorac Oncol
. 2020 Dec;
16(3):439-451.
PMID: 33309987
Introduction: The treatment of patients with EGFR-mutant NSCLC with vascular endothelial growth factor (VEGF) inhibitors in combination with EGFR inhibitors provides a greater benefit than EGFR inhibition alone, suggesting that...
3.
Nilsson M, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, et al.
Sci Transl Med
. 2020 Sep;
12(559).
PMID: 32878980
Acquired resistance to tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) remains a clinical challenge. Especially challenging are cases in which resistance emerges through EGFR-independent mechanisms, such as...
4.
Le X, Puri S, Negrao M, Nilsson M, Robichaux J, Boyle T, et al.
Clin Cancer Res
. 2018 Sep;
24(24):6195-6203.
PMID: 30228210
Purpose: Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of -mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described....